Next Article in Journal
Gaussian Blurring Technique for Detecting and Classifying Acute Lymphoblastic Leukemia Cancer Cells from Microscopic Biopsy Images
Next Article in Special Issue
Reliability and Responsiveness of a Novel Device to Evaluate Tongue Force
Previous Article in Journal
Impact of Dietary Administration of Seaweed Polysaccharide on Growth, Microbial Abundance, and Growth and Immune-Related Genes Expression of The Pacific Whiteleg Shrimp (Litopenaeus vannamei)
Previous Article in Special Issue
Effectiveness of Manual Trigger Point Therapy in Patients with Myofascial Trigger Points in the Orofacial Region—A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 13
Issue 2
10.3390/life13020345
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Preliminary Findings of the Efficacy of Botulinum Toxin in Temporomandibular Disorders: Uncontrolled Pilot Study

by
José A. Blanco-Rueda
1,
Antonio López-Valverde
2,*,
Antonio Márquez-Vera
1,
Roberto Méndez-Sánchez
3,
Eva López-García
4 and
Nansi López-Valverde
5
1
Instituto de Investigación Biomédica de Salamanca (IBSAL), University Hospital, 37007 Salamanca, Spain
2
Instituto de Investigación Biomédica de Salamanca (IBSAL), Department of Surgery, University of Salamanca, 37007 Salamanca, Spain
3
Department of Nursing and Physiotherapy, University of Salamanca, 37007 Salamanca, Spain
4
Primary Care, University Hospital “Rio Hortega”, 47012 Valladolid, Spain
5
Instituto de Investigación Biomédica de Salamanca (IBSAL), Department of Medicine and Medical Specialties, Universidad Alcalá de Henares, 28801 Madrid, Spain
*
Author to whom correspondence should be addressed.
Life 2023, 13(2), 345; https://doi.org/10.3390/life13020345
Submission received: 10 January 2023 / Revised: 17 January 2023 / Accepted: 20 January 2023 / Published: 28 January 2023
(This article belongs to the Special Issue Novel Diagnostic and Therapeutic Approaches in Temporomandibular Disorders (TMDs) and Myofascial Pain)
Browse Figures
Versions Notes

Abstract

:
Temporomandibular disorders are a common pathology affecting up to 70% of the population, with a maximum incidence in young patients. We used a sample of twenty patients recruited in the Maxillofacial Surgery Service of the University Hospital of Salamanca (Spain), who met the inclusion criteria, with unilateral painful symptomatology of more than three months’ duration. All patients were randomly treated by intramuscular and intra-articular injections of botulinum toxin (100 U) in eight predetermined points. Pain symptomatology was assessed by the visual analog scale (VAS) at the different locations, together with joint symptomatology, at baseline and six weeks after treatment. Adverse effects were also evaluated. In 85% of the patients, pain upon oral opening improved and 90% showed improvement in pain upon mastication. A total of 75% of the patients reported improvement in joint clicking/noise. Headaches improved or disappeared in 70% of the patients treated. Despite the limitations of the study and the preliminary results, intramuscular and intra-articular infiltrations with botulinum toxin were effective in the treatment of symptoms associated with temporomandibular disorders (TMDs), with minimal adverse effects.

1. Introduction

Temporomandibular disorders (TMDs) is a term that refers to a number of pathological conditions and disorders related to the temporomandibular joint (TMJ) and its associated musculoskeletal structures [1]. This set of disorders has previously been referred to as TMJ dysfunction syndrome, functional TMJ alterations, myofascial pain dysfunction syndrome, and temporomandibular pain dysfunction syndrome [2].
It is a common condition, with signs appearing in up to 60–70% of the population, yet only one in four people report the presence of any clinical symptoms, and only 5% of patients seek treatment [3]. Although it can appear at any age, the maximum incidence is observed in young adults, between 20 and 40 years of age, predominantly in women, in a ratio of 4/1 with respect to men [4].
More than 50% of TMDs manifest as myofascial pain, produced by parafunctional habits, such as clenching or bruxism. Its etiology remains poorly understood, but it is likely to be multifactorial and include anatomical, pathophysiological, psychosocial, environmental, biological, and genetic factors, including pre-disposing, triggering, and perpetuating factors [5]. Pain is the most common symptom, along with joint noises and functional limitation [6,7]; however, 40% of patients have an exponential reduction in symptoms and 50–90% have pain relief after conservative and rehabilitative treatment, such as physiotherapy, occlusal splints, orthodontic treatments, electrotherapy, etc. [8,9].
Therefore, multidisciplinary approaches are the ideal treatment option, always with the primary goal of resolving the patient’s pain and dysfunction; a recent systematic review suggested that a multidisciplinary approach involving physical medicine and rehabilitation physicians along with dentists is mandatory for the proper diagnosis and treatment of postural disorders in patients with TMDs. [10]
Nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, antiepileptics, and muscle relaxants are the most commonly used drugs in the treatment of acute pain, with NSAIDs being the most commonly used; however, despite the multiple NSAID options available, only naproxen has been shown to be effective in reducing pain [11]. Muscle relaxants may be prescribed along with NSAIDs if there is evidence of a muscle component, and tricyclic antidepressants are reserved for the treatment of chronic pain [12,13].
Botulinum toxin (BTX) is a neurotoxin produced by the anaerobic bacterium Clostridium botulinum with forty different serotypes and is one of the most potent toxins. Despite being considered lethal for many centuries, it was the first toxin used in the history of medicine [14]. Serotype A (the most studied for therapeutic purposes) is the most commonly used, although serotype B is occasionally used [15].
There is a gap in the scientific literature and only a limited number of studies refer to the efficacy of botulinum toxin type A (Botox) and its promising results in the improvement of painful myofascial symptoms [16,17,18,19,20] and although it is not considered a first-choice treatment for the management of TMDs, it could be a therapeutic option in situations where conventional treatments are ineffective.
This uncontrolled pilot study analyzed, after six weeks, the efficacy of intra-articular and facial muscle injections of botulinum toxin type A (Botox) on pain and joint clicking/noise associated with temporomandibular joint dysfunction pathology in a sample of twenty patients. Adverse side effects following botulinum toxin injection were also evaluated.

2. Materials and Methods

2.1. Patients

A sample of 20 patients (n = 20), who met the inclusion criteria for the study, were recruited at the Maxillofacial Surgery Department of the University Hospital of Salamanca. All patients agreed to participate in the research and signed the informed consent form. This study was conducted in accordance with the Helsinki Declaration and was approved by the Salamanca Health Area Drug Research Ethics Committee on 26 April 2021, Reference CEIm:PI 2021 04 734 and was registered in Clinicaltrials.gov (Identifier: NCT05651256).

2.2. Patient Description; Inclusion and Exclusion Criteria

The study included patients diagnosed with TMDs, according to the established diagnostic criteria [1], aged between 18 and 69 years (both included) and with unilateral painful symptomatology of more than three months’ duration. Patients previously treated with surgery/arthrocentesis of the TMJ; patients treated in the last six months with surgery in the cervicofacial region; patients who, at the time of inclusion in the study, were being treated in a “Pain Unit”; and patients who had previously received treatment with BTX were excluded. The mean age of the patients was 42.5 years and the distribution by sex was mostly in favor of women, at 17 of the 20 included (85%).

2.3. Treatments

The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX (Botox® 100 U, Allergan Pharmaceuticals, Westport, Ireland), kept refrigerated at 5 °C, in 1 mL of sterile saline solution at room temperature. Eight injection sites were marked: three located in the masseter muscle, two in the lateral pterygoid muscle, one in the TMJ and two in the temporalis muscle (Figure 1).
All patients included in the study (Figure 2) were randomized to receive a single dose at each injection site of the prepared solution by a single experienced blinded surgeon, 11 patients (55%) on the right side and 9 (45%) on the left side.
A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. [21,22], with a total dose of 100 U in each patient, distributed at the different injection sites: 40 U in the masseter muscle, (0.1 cc = 10 U), 20 U in the area of greatest hypertrophy (anterior inferior masseter, point 1), 10 U in the direction of the mandibular inferior border (point 2, middle inferior masseter) and 10 U in the area of the posterior inferior masseter (point 3); 20 U in the lateral pterygoid muscle (10 U extraorally between the zygomatic arch and sigmoid notch and 10 U intraorally, behind the maxillary tuberosity) (points 4 and 5); 20 U in the TMJ (point 6), 10mm anterior to the tragus and 2mm below the zygomatic arch; and 20 U in the anterior part of the temporalis muscle (points 7 and 8). The location of the injection point in the lateral pterygoid muscle was performed taking as a reference, in front of the coronoid process, behind the mandibular condyle, above the zygomatic arch and below the mandibular sigmoid notch, penetrating this area with the needle in an anteroposterior and cranial direction, with an angle of 15° with respect to the anterior border of the mandibular condyle; the injection needle in our study reached a depth of 2.5 cm ± 0.5 cm [23,24,25].
Life 13 00345 g002 550
Figure 2. Flow chart of progress through the phases of the study according to the CONSORT statement 2010 [26].
Figure 2. Flow chart of progress through the phases of the study according to the CONSORT statement 2010 [26].
Life 13 00345 g002

2.4. Pain Measurement

Pain was evaluated in different locations of the craniofacial region (temporalis muscle, masseter muscle, pterygoid muscle, trapezius muscle, externocleidomastoid muscle and temporomandibular joint), before BTX treatment and after six weeks, using the visual analog scale (VAS), in a range from 0 to 10, considering a value of 0 as no pain and 10 as maximum pain.

2.5. Adverse Effect Assessment

Side effects evaluated included warmth, flushing and hematoma at the injection site, swallowing alteration, contralateral muscle contracture or pain and presence of abnormal jaw movements.

3. Results

3.1. Pain Reduction

The average values of pain intensity, in the different locations, before and after treatment, respectively, are presented in Figure 3.
Before treatment, 19 patients (95%) presented with joint clicking/noise, 17 patients (85%) with headaches, 19 patients (95%) with pain upon opening the mouth and 18 (90%) with pain upon chewing.
At six weeks after treatment, 75% of the patients reported an improvement in joint clicks/noises. Regarding headaches, 70% showed an improvement/disappearance, and only 1 patient (5%) showed a very slight improvement. Eighty-five percent of the patients showed improvement in pain on headaches and 90% showed improvement in pain on chewing. Pain intensity decreased in all areas injected with BTX; however, three patients (15%) reported minimal or no decrease in pain intensity in the different locations.

3.2. Adverse Events

It is noteworthy that most of the patients did not report having suffered any adverse event after treatment.
The most frequent adverse effect was the appearance of abnormal jaw movements, which was present in four patients (20%); however, two patients (10%) reported that these abnormal movements were only present in the first few days after treatment, while two others reported that they continued to suffer them.
Two of the patients (10%) reported a sensation of flushing/heat in the injection area in the days following treatment, and only one of the patients (5%) reported the appearance of hematoma in the injected area. Three patients (15%) reported the appearance of muscle contracture/pain on the side contralateral to the injection; however, it is noteworthy that swallowing alteration did not appear in any of the patients (Figure 4).

4. Discussion

Botulinum toxin has evolved from being a toxicant to a versatile therapeutic tool for a growing list of pathologies; however, treatment with BTX remains controversial and there are not many studies evaluating its efficacy in the treatment of TMDs, most of them being in favor of its use and its ability to alleviate pain associated with this pathology [27,28,29,30].
Freund et al. in 1999 [31] were the first to report preliminary results on the benefits of BTX on pain, function and mouth opening in a sample of 15 patients diagnosed with TMDs. Subsequently, these same investigators, in an expanded sample of 46 patients, demonstrated that intramuscular injections of BTX-A produced significant improvements in pain, function and mouth opening, reducing the severity of symptoms and improving the functional abilities of patients with TMDs, and that these effects would extend beyond its capacity as a muscle relaxant [32]. Recently, several studies and systematic reviews have focused on the benefits of BTX in patients with TMDs [33,34,35,36,37], although there are discrepancies regarding the efficacy of BTX in this pathology, mainly based on methodological errors. Laskin pointed out that many studies do not address the etiology and focus only on symptomatic treatment and that conservative treatments would be equally effective; however, he acknowledges that the etiology of pain and masticatory muscle dysfunction remains unknown [10,38].
Preliminary results of our study found a beneficial effect in 85% of patients with TMDs. These results coincided with those obtained by Sidebottom et al. [27] who, in a prospective study on 62 patients, with a mean age of 42.5 years and (like our study) a preponderance in the sample of the female sex, reported a significant reduction in pain, greater than 90% in 79% of patients treated with a single dose of BTX, concluding that intramuscular injections of BTX, although not guaranteeing complete resolution of myofascial pain, often produce a beneficial effect on symptomatology, and should be considered as an alternative treatment for masticatory myofascial pain in the face of failure of conservative treatments.
The facial areas injected with BTX differ in different studies. Some inject only the masseter muscle [39], others the masseter and temporalis [40,41] and others use injection in the temporalis, masseter, and external pterygoid muscles [42]. Intramuscular injection with BTX in the masseter muscle is often used in the treatment of myofascial syndrome, whose etiological factors lie mainly in fatigue or spasm of the masticatory muscles, with a concomitant arthralgia of the TMJ [27,43]. Schwartz and Freund base the diagnosis of TMDs on two etiologies, one anatomical and the other functional, with two critical areas, the arthrogenic pathology (intracapsular) and the myogenic pathology, originating in the musculature, recommending their simultaneous approach [44]; however, Batifol [45] recommends intra-articular injections exclusively if the pain is chronic. In accordance with these recommendations, our study included patients with a history of pain lasting more than 3 months.
Although BTX was initially only used in the treatment of focal dystonia, it has been shown to provide relief from migraine and tension headaches and neck pain (cervical dystonia), suggesting a possible role in the treatment of TMDs [46,47,48,49,50]; a review by Ihde and Konstantinovic concluded that BTX appears to be relatively safe and effective in the treatment of cervical dystonia and chronic facial pain associated with masticatory hyperactivity [51]. Similarly, Blitzer and Sulica demonstrated its effectiveness in the treatment of torticollis, including as involved muscles the sternocleidomastoid, trapezius, semispinalis capitis, splenius capitis, levator scapulae, and minor paraspinal muscles [52] and that BTX was the most frequently injected substance, intramuscularly, in the treatment of TMDs [53].
Our study, in accordance with these results, found a disappearance of headaches in 70% of the patients treated, although 15% of the patients reported not having found relief from painful symptomatology. In our study, we combined BTX infiltration in the masseter, temporalis, and pterygoid muscles with intra-articular infiltration, obtaining excellent results on pain in the cervicofacial musculature (Figure 3).
On the other hand, intra-articular infiltration of BTX has demonstrated its efficacy in reducing pain [54]. Lora et al. demonstrated in a study in rats the strong antinociceptive effect of intra-articular injection of BTX-A [55]. Intra-articular injection of BTX inhibits inflammatory mediators, reduces neuropeptide release from joint nociceptors and thus reduces neurogenic inflammation and joint pain [56]. Our study found in 85% of treated patients an improvement of pain on mouth opening and 90% showed improvement of pain on chewing. Furthermore, in 75% of the treated patients, an improvement in joint clicking/noise was observed. These results would agree with those obtained by Bakke et al. [57], who, by BTX-A injections into the lateral pterygoid muscle, temporarily reduced the muscle action, but the clicking was permanently eliminated and did not reappear during the 1-year observation period, obtaining a small but clear positional improvement in the disc–condyle relationship. Similarly, other studies [58,59,60] with BTX-A injections into the lateral pterygoid muscle reported benefits on temporomandibular clicking.
The dose ranges are also discrepant in the different studies. Schwartz and Freund recommend doses like those used by us: 25–50 U in the masseter muscle, 5–25 U in the temporalis muscle and 5–25 in the pterygoid muscle [44]. Batifol recommends for intra-articular injection doses similar to those used in our study [45].
Regarding adverse effects, Ihde and Konstantinovic, in a review identifying randomized clinical trials evaluating patients treated with botulinum toxin, found that the adverse effects were mild and transient [61]; similarly, a systematic review by Machado et al. [62] found no significant difference in adverse effects between BTX-A and a placebo. In our study, only four patients (20%) reported them, reporting their disappearance within a few days.
Despite these results, we are aware of the limitations of the study: on the one hand, the small sample size, although authors such as Sipahi Calis et al. and Patel et al. [42,63] base their studies of the effect of BTX on TMDs on sample sizes similar to ours, at 25 and 20 patients, respectively; on the other hand, the evaluation was performed six weeks after the infiltrations, clearly resulting in a reduced evaluation time. In addition, joint and muscle infiltrations, at the same time, could lead to biases in the results. Nevertheless, we present a pilot study with preliminary results.

5. Conclusions

Despite the limitations of the study and presenting preliminary results, we believe that multiple intramuscular and intra-articular infiltrations with BTX-A, with a total dose of 100 U, are effective (at least temporarily) in relieving TMJ pain and clicking and noises, with minimal adverse effects. Future ongoing controlled studies, with a larger sample of patients and longer-term follow-up, will allow comparison of the results.

Author Contributions

Conceptualization, J.A.B.-R. and N.L-V.; methodology A.L.-V.; validation, N.L.-V. and A.M.-V.; formal analysis, E.L.-G. and R.M.-S.; investigation, J.A.B.-R.; writing—original draft preparation, A.L.-V. and N.L.-V.; writing—review and editing, A.L.-V. and N.L.-V.; supervision, A.L.-V. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Salamanca Health Area Drug Research Ethics Committee on 26 April 2021, Reference CEIm:PI 2021 04 734.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

https://beta.clinicaltrials.gov/.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Schiffman, E.; Ohrbach, R.; Truelove, E.; Look, J.; Anderson, G.; Goulet, J.P.; List, T.; Svensson, P.; Gonzalez, Y.; Lobbezoo, F.; et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: Recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J. Oral Facial Pain Headache 2014, 28, 6–27. [Google Scholar] [CrossRef] [PubMed]
  2. Okeson, J.P. Current terminology and diagnostic classification schemes. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontology 1997, 83, 61–64. [Google Scholar] [CrossRef] [PubMed]
  3. Liu, F.; Steinkeler, A. Epidemiology, diagnosis, and treatment of temporomandibular disorders. Dent. Clin. 2013, 57, 465–479. [Google Scholar] [CrossRef] [PubMed]
  4. Kobayashi, F.Y.; Gavião, M.B.D.; Montes, A.B.M.; Marquezin, M.C.S.; Castelo, P.M. Evaluation of orofacial function in young subjects with temporomandibular disorders. J. Oral Rehabil. 2014, 41, 496–506. [Google Scholar] [CrossRef] [PubMed]
  5. Baba, K.; Tsukiyama, Y.; Yamazaki, M.; Clark, G.T. A review of temporomandibular disorder diagnostic techniques. J. Prosthet. Dent. 2001, 86, 184–194. [Google Scholar] [CrossRef] [PubMed]
  6. Gauer, R.L.; Semidey, M.J. Diagnosis and treatment of temporomandibular disorders. Am. Fam. Physician. 2015, 91, 378–386. [Google Scholar]
  7. Lomas, J.; Gurgenci, T.; Jackson, C.; Campbell, D. Temporomandibular dysfunction. Aust. J. Gen. Pract. 2018, 47, 212–215. [Google Scholar] [CrossRef] [Green Version]
  8. Shoohanizad, E.; Garajei, A.; Enamzadeh, A.; Yari, A. Nonsurgical management of temporomandibular joint autoimmune disorders. AIMS Public Health. 2019, 6, 554–567. [Google Scholar] [CrossRef] [PubMed]
  9. Ferrillo, M.; Marotta, N.; Giudice, A.; Calafiore, D.; Curci, C.; Fortunato, L.; Ammendolia, A.; de Sire, A. Effects of Occlusal Splints on Spinal Posture in Patients with Temporomandibular Disorders: A Systematic Review. Healthcare 2022, 10, 739. [Google Scholar] [CrossRef]
  10. Ferrillo, M.; Ammendolia, A.; Paduano, S.; Calafiore, D.; Marotta, N.; Migliario, M.; Fortunato, L.; Giudice, A.; Michelotti, A.; de Sire, A. Efficacy of rehabilitation on reducing pain in muscle-related temporomandibular disorders: A systematic review and meta-analysis of randomized controlled trials. J. Back Musculoskelet. Rehabil. 2022, 35, 921–936. [Google Scholar] [CrossRef]
  11. Ta, L.E.; Dionne, R.A. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: A randomized placebo-controlled comparison of celecoxib to naproxen. Pain 2004, 111, 13–21. [Google Scholar] [CrossRef] [PubMed]
  12. Herman, C.R.; Schiffman, E.L.; Look, J.O.; Rindal, D.B. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: A randomized clinical trial. J. Orofac. Pain. 2002, 16, 64–70. [Google Scholar] [PubMed]
  13. Hersh, E.V.; Balasubramaniam, R.; Pinto, A. Pharmacologic management of temporomandibular disorders. Oral Maxillofac Surg. Clin. N. Am. 2008, 20, 197–210. [Google Scholar] [CrossRef] [PubMed]
  14. Park, J.; Park, H.J. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins 2017, 9, 260. [Google Scholar] [CrossRef] [Green Version]
  15. Malgorzata, P.; Piotr, C.; Edward, K. The Mechanism of the Beneficial Effect of Botulinum Toxin Type a Used in the Treatment of Temporomandibular Joints Dysfunction. Mini. Rev. Med. Chem. 2017, 17, 445–450. [Google Scholar] [CrossRef]
  16. Fallah, H.M.; Currimbhoy, S. Use of botulinum toxin A for treatment of myofascial pain and dysfunction. J. Oral Maxillofac Surg. 2012, 70, 1243–1245. [Google Scholar] [CrossRef]
  17. Patel, J.; Cardoso, J.A.; Mehta, S. A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism. Br. Dent. J. 2019, 226, 667–672. [Google Scholar] [CrossRef]
  18. Serrera-Figallo, M.A.; Ruiz-de-León-Hernández, G.; Torres-Lagares, D.; Castro-Araya, A.; Torres-Ferrerosa, O.; Hernández-Pacheco, E.; Gutierrez-Perez, J.L. Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins 2020, 12, 112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. von Lindern, J.J.; Niederhagen, B.; Bergé, S.; Appel, T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J. Oral Maxillofac. Surg. 2003, 61, 774–778. [Google Scholar] [CrossRef]
  20. Muñoz Lora, V.R.M.; Del Bel Cury, A.A.; Jabbari, B.; Lacković, Z. Botulinum Toxin Type A in Dental Medicine. J. Dent. Res. 2019, 98, 1450–1457. [Google Scholar] [CrossRef]
  21. Kim, N.H.; Park, R.H.; Park, J.B. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast. Reconstr. Surg. 2010, 125, 1693–1705. [Google Scholar] [CrossRef] [PubMed]
  22. Ho, K.Y.; Tan, K.H. Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review. Eur. J. Pain. 2007, 11, 519–527. [Google Scholar] [CrossRef] [PubMed]
  23. Mesa-Jiménez, J.A.; Sánchez-Gutiérrez, J.; de-la-Hoz-Aizpurua, J.L.; Fernández-de-las-Peñas, C. Cadaveric validation of dry needle placement in the lateral pterygoid muscle. J. Manip. Physiol. Ther. 2015, 38, 145–150. [Google Scholar] [CrossRef] [PubMed]
  24. Gonzalez-Perez, L.M.; Infante-Cossio, P.; Granados-Nuñez, M.; Urresti-Lopez, F.J. Treatment of temporomandibular myofascial pain with deep dry needling. Med. Oral Patol. Oral Cir. Bucal. 2012, 17, e781-5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kucukguven, A.; Demiryurek, M.D.; Kucukguven, M.B.; Vargel, I. A Novel Injection Technique to the Lateral Pterygoid Muscle for Temporomandibular Disorders: A Cadaveric Study. Plast. Reconstr. Surg. 2021, 148, 785e–790e. [Google Scholar] [CrossRef]
  26. Moher, D.; Hopewell, S.; Schulz, K.F.; Montori, V.; Gøtzsche, P.C.; Devereaux, P.J.; Elbourne, D.; Egger, M.; Altman, D.G. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. Int. J. Surg. 2012, 10, 28–55. [Google Scholar] [CrossRef] [Green Version]
  27. Sidebottom, A.J.; Patel, A.A.; Amin, J. Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br. J. Oral Maxillofac. Surg. 2013, 51, 199–205. [Google Scholar] [CrossRef]
  28. Laskin, D.M. The Use of Botulinum Toxin for the Treatment of Myofascial Pain in the Masticatory Muscles. Oral Maxillofac. Surg. Clin. N. Am. 2018, 30, 287–289. [Google Scholar] [CrossRef]
  29. Soares, A.; Andriolo, R.B.; Atallah, A.N.; da Silva, E.M. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst. Rev. 2014, 2014, CD007533. [Google Scholar]
  30. Zhou, J.Y.; Wang, D. An update on botulinum toxin A injections of trigger points for myofascial pain. Curr. Pain Headache Rep. 2014, 18, 386. [Google Scholar] [CrossRef]
  31. Freund, B.; Schwartz, M.; Symington, J.M. The use of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings. J. Oral Maxillofac. Surg. 1999, 57, 916–920. [Google Scholar] [CrossRef] [PubMed]
  32. Freund, B.; Schwartz, M.; Symington, J.M. Botulinum toxin: New treatment for temporomandibular disorders. Br. J. Oral Maxillofac. Surg. 2000, 38, 466–471. [Google Scholar] [CrossRef]
  33. Nayyar; Kumar, P.; Nayyar, P.V.; Singh, A. BOTOX: Broadening the Horizon of Dentistry. J. Clin. Diagn. Res. 2014, 8, ZE25–ZE29. [Google Scholar] [PubMed]
  34. Hoque, A.; McAndrew, M. Use of botulinum toxin in dentistry. N. Y. State Dent. J. 2009, 75, 52–55. [Google Scholar] [PubMed]
  35. Al-Wayli, H. Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study. J. Clin. Exp. Dent. 2017, 9, e112–e117. [Google Scholar] [CrossRef]
  36. Satriyasa, B.K. Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: A literature review of clinical use and pharmacological aspect. Clin. Cosmet. Investig. Dermatol. 2019, 12, 223–228. [Google Scholar] [CrossRef] [Green Version]
  37. Srivastava, S.; Kharbanda, S.; Pal, U.S.; Shah, V. Applications of botulinum toxin in dentistry: A comprehensive review. Natl. J. Maxillofac. Surg. 2015, 6, 152–159. [Google Scholar]
  38. Laskin, D.M. Botulinum toxin A in the treatment of myofascial pain and dysfunction: The case against its use. J. Oral Maxillofac. Surg. 2012, 70, 1240–1242. [Google Scholar] [CrossRef]
  39. Pihut, M.; Ferendiuk, E.; Szewczyk, M.; Kasprzyk, K.; Wieckiewicz, M. The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache. J. Headache Pain 2016, 17, 29. [Google Scholar] [CrossRef] [Green Version]
  40. Chikhani, L.; Dichamp, J. Bruxisme, syndrome algodysfonctionnel des articulations temporo-mandibulaires et toxine botulique [Bruxism, temporo-mandibular dysfunction and botulinum toxin]. Ann. Readapt. Med. Phys. 2003, 46, 333–337. [Google Scholar] [CrossRef]
  41. Hosgor, H.; Altindis, S. Efficacy of botulinum toxin in the management of temporomandibular myofascial pain and sleep bruxism. J. Korean Assoc. Oral Maxillofac. Surg. 2020, 46, 335–340. [Google Scholar] [CrossRef] [PubMed]
  42. Patel, A.A.; Lerner, M.Z.; Blitzer, A. IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder. Ann. Otol. Rhinol. Laryngol. 2017, 126, 328–333. [Google Scholar] [CrossRef] [PubMed]
  43. Thomas, N.J.; Aronovich, S. Does Adjunctive Botulinum Toxin a Reduce Pain Scores When Combined with Temporomandibular Joint Arthroscopy for the Treatment of Concomitant Temporomandibular Joint Arthralgia and Myofascial Pain? J. Oral Maxillofac. Surg. 2017, 75, 2521–2528. [Google Scholar] [CrossRef] [PubMed]
  44. Schwartz, M.; Freund, B. Treatment of temporomandibular disorders with botulinum toxin. Clin. J. Pain 2002, 18 (Suppl. S6), S198–S203. [Google Scholar] [CrossRef]
  45. Batifol, D. Les différents types d’injection pour traiter les dysfonctions de l’articulation temporomandibulaire [Different types of injection in temporomandibular disorders (TMD) treatment]. Rev. Stomatol. Chir. Maxillo-Faciale Chir. Orale 2016, 117, 256–258. [Google Scholar] [CrossRef]
  46. Gadhia, K.; Walmsley, D. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions. Evid. Based Dent. 2009, 10, 53. [Google Scholar] [CrossRef] [Green Version]
  47. Blumenfeld, A.M.; Stark, R.J.; Freeman, M.C.; Orejudos, A.; Manack Adams, A. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J. Headache Pain 2018, 19, 13. [Google Scholar] [CrossRef] [Green Version]
  48. Binder, W.J.; Brin, M.F.; Blitzer, A.; Schoenrock, L.D.; Pogoda, J.M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol. Head Neck Surg. 2000, 123, 669–676. [Google Scholar] [CrossRef]
  49. Freund, B.; Schwartz, M. Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache J. Head Face Pain 2000, 40, 231–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Freund, B.; Schwartz, M. Treatment of whiplash associated with neck pain with botulinum toxin-A: A pilot study. J. Rheumatol. 2000, 27, 481–484. [Google Scholar]
  51. Ihde, S.K.; Konstantinovic, V.S. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: An evidence-based review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontology 2007, 104, e1–e11. [Google Scholar] [CrossRef] [PubMed]
  52. Blitzer, A.; Sulica, L. Botulinum toxin: Basic science and clinical uses in otolaryngology. Laryngoscope 2000, 111, 218–226. [Google Scholar] [CrossRef] [PubMed]
  53. Nowak, Z.; Cheęciński, M.; Nitecka-Buchta, A.; Bulanda, S.; Ilczuk-Rypuła, D.; Postek-Stefańska, L.; Baron, S. Intramuscular Injections and Dry Needling within Masticatory Muscles in Management of Myofascial Pain. Systematic Review of Clinical Trials. Int. J. Environ. Res. Public Health 2021, 18, 9552. [Google Scholar] [CrossRef] [PubMed]
  54. Sari, B.C.; Develi, T. The effect of intraarticular botulinum toxin-A injection on symptoms of temporomandibular joint disorder. J. Stomatol. Oral Maxillofac. Surg. 2022, 123, e316–e320. [Google Scholar] [CrossRef] [PubMed]
  55. Lora, V.R.; Clemente-Napimoga, J.T.; Abdalla, H.B.; Macedo, C.G.; Canales, G.T.; Barbosa, C.M. Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats. Toxicon 2017, 129, 52–57. [Google Scholar] [CrossRef]
  56. Drinovac Vlah, V.; Filipović, B.; Bach-Rojecky, L.; Lacković, Z. Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region. Eur. J. Pain. 2018, 22, 583–591. [Google Scholar] [CrossRef] [PubMed]
  57. Bakke, M.; Møller, E.; Werdelin, L.M.; Dalager, T.; Kitai, N.; Kreiborg, S. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2005, 100, 693–700. [Google Scholar] [CrossRef]
  58. Emara, A.S.; Faramawey, M.I.; Hassaan, M.A.; Hakam, M.M. Botulinum toxin injection for management of temporomandibular joint clicking. Int. J. Oral Maxillofac. Surg. 2013, 42, 759–764. [Google Scholar] [CrossRef]
  59. Karacalar, A.; Yilmaz, N.; Bilgici, A.; Baş, B.; Akan, H. Botulinum toxin for the treatment of temporomandibular joint disk disfigurement: Clinical experience. J. Craniofac. Surg. 2005, 16, 476–481. [Google Scholar] [CrossRef]
  60. Rezazadeh, F.; Esnaashari, N.; Azad, A.; Emad, S. The effects of botulinum toxin A injection on the lateral pterygoid muscle in patients with a painful temporomandibular joint click: A randomized clinical trial study. BMC Oral Health 2022, 22, 217. [Google Scholar] [CrossRef]
  61. Truong, D.; Brodsky, M.; Lew, M.; Brashear, A.; Jankovic, J.; Molho, E.; Orlova, O.; Timerbaeva, S. Global Dysport Cervical Dystonia Study Group. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Park. Relat. Disord. 2010, 16, 316–323. [Google Scholar] [CrossRef] [PubMed]
  62. Machado, D.; Martimbianco, A.L.C.; Bussadori, S.K.; Pacheco, R.L.; Riera, R.; Santos, E.M. Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis. J. Pain 2020, 21, 281–293. [Google Scholar] [CrossRef] [PubMed]
  63. Sipahi Calis, A.; Colakoglu, Z.; Gunbay, S. The use of botulinum toxin-a in the treatment of muscular temporomandibular joint disorders. J. Stomatol. Oral Maxillofac. Surg. 2019, 120, 322–325. [Google Scholar] [CrossRef] [PubMed]
Life 13 00345 g001 550
Figure 1. Injection points. 1, 2 and 3, masseter muscle; 4, lateral pterygoid muscle (extra-oral injection); 5, lateral pterygoid muscle (intra-oral injection); 6, TMJ; 7 and 8, anterior temporalis muscle fibers.
Figure 1. Injection points. 1, 2 and 3, masseter muscle; 4, lateral pterygoid muscle (extra-oral injection); 5, lateral pterygoid muscle (intra-oral injection); 6, TMJ; 7 and 8, anterior temporalis muscle fibers.
Life 13 00345 g001
Life 13 00345 g003 550
Figure 3. Assessment of pain intensity in the cervicofacial musculature by VAS before and after intramuscular injection of BTX.
Figure 3. Assessment of pain intensity in the cervicofacial musculature by VAS before and after intramuscular injection of BTX.
Life 13 00345 g003
Life 13 00345 g004 550
Figure 4. Adverse effects after BTX treatment.
Figure 4. Adverse effects after BTX treatment.
Life 13 00345 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Blanco-Rueda, J.A.; López-Valverde, A.; Márquez-Vera, A.; Méndez-Sánchez, R.; López-García, E.; López-Valverde, N. Preliminary Findings of the Efficacy of Botulinum Toxin in Temporomandibular Disorders: Uncontrolled Pilot Study. Life 2023, 13, 345. https://doi.org/10.3390/life13020345

AMA Style

Blanco-Rueda JA, López-Valverde A, Márquez-Vera A, Méndez-Sánchez R, López-García E, López-Valverde N. Preliminary Findings of the Efficacy of Botulinum Toxin in Temporomandibular Disorders: Uncontrolled Pilot Study. Life. 2023; 13(2):345. https://doi.org/10.3390/life13020345

Chicago/Turabian Style

Blanco-Rueda, José A., Antonio López-Valverde, Antonio Márquez-Vera, Roberto Méndez-Sánchez, Eva López-García, and Nansi López-Valverde. 2023. "Preliminary Findings of the Efficacy of Botulinum Toxin in Temporomandibular Disorders: Uncontrolled Pilot Study" Life 13, no. 2: 345. https://doi.org/10.3390/life13020345

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop